Pilot Sub-Study of the Effect of Hepatitis C Cure by Glecaprevir/Pibrentasvir on the Gut Microbiome of Patients with Chronic Hepatitis C Genotypes 1 to 6 in the Mythen Study

In this small pilot sub-study, longitudinal gut microbiota composition changes, after successful treatment of hepatitis C virus (HCV) with the co-formulated glecaprevir/pibrentasvir (GLE/PIB), were analyzed before treatment (baseline) and 12 weeks post-treatment. Participating patients provided a fr...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Pharmaceuticals
المؤلفون الرئيسيون:	Bahtiyar Yilmaz, Lisa Ruckstuhl, Beat Müllhaupt, Lorenzo Magenta, Melanie Harrer Kuster, Olivier Clerc, Ralph Torgler, Nasser Semmo
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	MDPI AG 2021-09-01
الموضوعات:	HCV gut microbiota alpha-diversity beta-diversity direct-acting antivirals
الوصول للمادة أونلاين:	https://www.mdpi.com/1424-8247/14/9/931